| Project/Area Number |
26460160
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Drug development chemistry
|
|---|
| Research Institution | Osaka University of Pharmaceutical Sciences |
|---|
Principal Investigator |
Harusawa Shinya 大阪薬科大学, 薬学部, 教授(移行) (90167601)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
高岡 昌徳 大阪薬科大学, 薬学部, 教授 (50140231)
坂口 実 大阪薬科大学, 薬学部, 准教授(移行) (90221267)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | H3R / アンタゴニスト / イソチオウレア / 合成法 / 乳癌 / 増殖抑制 / アポトーシス / 効率合成法 / 癌 / 乳癌細胞 / ヒト乳癌細胞 |
|---|
| Outline of Final Research Achievements |
Histamine H3 antagonists have been expected as useful drugs on the central nervous systems. We reported a new type H3 potent antagonist OUP-186 (2013),which exhibited a receptor sub-type selectivity as well as a species-selective difference in antagonist affinities. On the otherhand, as relationships between H3R and cancer proliferation have been reported, we expected an cancer-attenuation of OUP-186 against breast cancer cells. After various investigations, we found the potent inhibitory activities of OUP-186 and its derivatives against the proliferation of human breast cancer cell lines. These successful rsults were reveled on some jouranals: Synthesis (2015) and BioChem. Biophys. Res. Commun.(2016) et al.
|
